FIG. 1


mm3
2500
2000
1500
1000
500
0
Cisplatin, x2 cycles
Cisplatin + CBP501, x2 cycles
Cisplatin + CBP501 + TSA005, x2 cycles
Cisplatin + CBP501 + anti-CTLA-4 Ab, x1 cycle
Cisplatin + CBP501 + anti-CTLA-4 Ab + TSA005, x1 cycle
Days
1
3
5
7
9
11
13
15
Treatment cycle 1
Day 1 to 5
Treatment cycle 2
Day 10 to 14


Cisplatin+CBP501+αCTLA4+TSA009
Cisplatin+CBP501+αCTLA4
Cisplatin+CBP501+αCTLA4+TSA005
mm3
1600
1400
1200
1000
800
600
400
200
0
1
3
5
7
9
11
13
15
17
days after first treatment

FIG. 2

FIG. 3


Including dead cells
Live cell gated
DMSO
5 µM CPT
TSA005
Cy5.5 version
TSA006
Cy5.5 version
FITC
APC-A700-A

FIG. 4A


Measured tumor volume of
BALB/c mice with CT-26 colon carcinoma
(mean values +/- SEM)
Vehicle+Cisplatin+CBP501+anti-CTLA4
TSA006+Cisplatin+CBP501+anti-CTLA4
TSA005+Cisplatin+CBP501+anti-CTLA4
measured tumor volume (mm³)
900
800
700
600
500
400
300
200
100
1
3
5
7
9
11
13
15
days after first treatment
Vehicle or <Cisplatin+CBP501> iv on day1
Anti-CTLA-4 ip on day2 and 4
Vehicle, TSA005 or TSA006 iv twice on day 2 and once on day3

FIG. 4B


CDDP+CBP501+αCTLA4+Saline
Tumor Size (mm3)
1000
900
800
700
600
500
400
300
200
100
0
1
6
11
Days after first treatment
00F01
00F02
00F03
00F04
00F05
00F06

FIG. 4C


CDDP+CBP501+αCTLA4+TSA005
Tumor Size (mm3)
1000
900
800
700
600
500
400
300
200
100
0
1
6
11
Days after first treatment
01F01
01F02
01F03
01F04
01F05
01F06

FIG. 4D


CDDP+CBP501+αCTLA4+TSA006
Tumor Size (mm3)
1000
900
800
700
600
500
400
300
200
100
0
1
6
11
Days after first treatment
02F01
02F02
02F03
02F04
02F05
02F06

FIG. 5

Distribution of the Cy5.5 version of TSA006 (TSA013) in balb/c mouse.